Cathie Wood's ARK Trades Tesla and Teradyne Stock, Buys Crispr

Cathie Wood's ARK trades Tesla and Teradyne stock, buys Crispr

Cathie Wood's ARK Investment Management bought more than $60 million of Crispr Therapeutics shares on Tuesday, while paring its holdings in Tesla and Teradyne.

The ARK Genomic Revolution ETF bought 859,179 shares of Crispr, a gene-editing company, according to its daily trade summary. That increased ARK's stake in Crispr by 1.2% to 4.3%.

ARK sells Tesla and Teradyne stocks

Meanwhile, ARK sold 184,308 Tesla shares, reducing its stake by 0.2% to 8.2%. The ETF also sold 54,891 Teradyne shares, decreasing its stake by 0.2% to 1.6%.

The ARK Autonomous Technology & Robotics ETF sold 1.1 million shares of Tesla, reducing its stake by 0.4% to 6.9%. The ETF also sold 87,774 Teradyne shares, decreasing its stake by 0.3% to 1.7%.

ARK's trades come as the market continues to gyrate amid concerns about inflation and interest rate hikes. Crispr's shares have outperformed the broader market this year, rising more than 40%.

Crispr is a clinical-stage gene-editing company focused on developing transformative therapies for serious diseases. The company's lead product candidate, CTX001, is a treatment for sickle cell disease and beta-thalassemia.